UNSPSC 51141556: Eslicarbazepine

This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S5VXA428R4. European Medicines Agency schedules Eslicarbazepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27751. Eslicarbazepine generally arises in the molecular formula C15H14N2O2. The term ESLICARBAZEPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53.) Most nations schedule Eslicarbazepine under HS 29339930 and SITC 51577.

As of Q4 2014, ESLICARBAZEPINE remains the US FDA Preferred Term for this commodity. Eslicarbazepine bears US NLM identifiers UMLS ID C2725260 and NCI Concept Code C81473. SMILES: C1CCC2C(C1)C[C@@H](C3CCCCC3N2C(=O)N)O.

UNSPSC 51141556 Eslicarbazepine is a Commodity code that in practice catalogs pharmaceutical products procured by state and local health agencies, though recent solicitation activity under this specific code shows minimal relevant procurement. The single recent opportunity in the block—Seminole County, Florida's IFB for naloxone and drug deactivation systems—is tagged to this anticonvulsant drug code but represents a public health supply procurement fundamentally outside the code's nominal scope. The mismatch suggests either data-tagging error or an overly broad category assignment that does not reflect actual buying patterns for this specific pharmaceutical line item.

Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the response deadline was July 26, 2023. The procurement required electronic submission through the county's e-Procurement Portal, drug-free workplace certification, E-Verify compliance, workers' compensation and commercial general liability insurance, and a fixed-fee pricing model with a two-year initial term and optional one-year renewal. The contract included potential FEMA funding and associated federal compliance obligations under the Clean Air Act and Federal Water Pollution Control Act. Vendors bore all shipping and delivery costs. No explicit set-aside designations were noted. The limited recent opportunity record and the evident mismatch between the code's pharmaceutical scope and the health-supply buying actually occurring suggest this code warrants close attention only if your firm specifically supplies eslicarbazepine tablets or similar anticonvulsants to state Medicaid programs, corrections departments, or mental health authorities—channels not yet visible in the current opportunity stream.